

1 **Effects of face masks and ventilation on the risk of SARS-CoV-2 respiratory**
2 **transmission in public toilets: a quantitative microbial risk assessment**

3

4 Thammanitchpol Denpetkul¹, Oranoot Sittipunsakda¹, Monchai Pumkaew², Skorn Mongkolsuk^{3,4},
5 and Kwanrawee Sirikanachana^{3,4,*}

6

7 ¹Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand 10400; ²Environmental
8 Engineering and Disaster Management Program, School of Multidisciplinary, Mahidol University,
9 Kanchanaburi Campus, Sai Yok, Kanchanaburi, Thailand, 71150; ³Research Laboratory of
10 Biotechnology, Chulabhorn Research Institute, Bangkok, Thailand 10210; ⁴Center of Excellence on
11 Environmental Health and Toxicology (EHT), Ministry of Education, Bangkok, Thailand 10400

12 *kwanrawee@cri.or.th

13

14 Short title: toilet user risks to COVID-19 infection via inhalation


15

16 **Highlights**

- 17 - The use of public toilets poses a risk of SARS-CoV-2 respiratory transmission
18 - Highest risks generated in the order of sneezing, coughing, and breathing
19 - No gender differences in risk by counteracting dwell times and inhalation rates
20 - Ventilation did not reduce risk even at 20 ACH, beyond the WHO-recommended value
21 - N95 and surgical masks offer the most effective risk mitigation to toilet users

22

23 **Graphical abstract**



24

25

26 **Abstract**

27 Public toilets could increase the risk of COVID-19 infection via airborne transmission; however,
28 related research is limited. We aimed to estimate SARS-CoV-2 infection risk through respiratory
29 transmission using a quantitative microbial risk assessment framework by retrieving SARS-CoV-
30 2 concentrations from the swab tests of 251 Thai patients. Three virus-generating scenarios were
31 investigated: an infector breathing, breathing with a cough, and breathing with a sneeze. Infection
32 risk (97.5th percentile) was as high as 10^{-3} with breathing and increased to 10^{-1} with a cough or
33 sneeze, thus all higher than the risk benchmark of 5×10^{-5} per event. No significant gender
34 differences for toilet users (receptors) were noted. The highest risk scenario of breathing and a

35 sneeze was further evaluated for risk mitigation measures. Risk mitigation to lower than the
36 benchmark succeeded only when the infector and receptor simultaneously wore an N95 respirator
37 or surgical mask and when the receptor wore an N95 respirator and the infector wore a denim
38 fabric mask. Ventilation up to 20 air changes per hour (ACH), beyond the 12-ACH suggested by
39 the WHO, did not mitigate risk. Virus concentration, volume of expelled droplets, and receptor
40 dwell time were identified as the main contributors to transmission risk.

41

42 **Keywords:** aerosol, COVID-19, mask, restroom, risk management, ventilation

43

44 **Introduction**

45 The coronavirus disease 2019 (COVID-19) pandemic has affected the global population since its
46 first emergence in December 2019. The three main transmission routes of the severe acute
47 respiratory syndrome coronavirus 2 (SARS-CoV-2), an etiological agent of COVID-19, have been
48 identified as (1) the inhalation of respiratory fluids carrying infectious viruses, (2) direct splashes
49 or sprays of infectious respiratory droplets and aerosol particles, and (3) the touching of
50 contaminated surfaces (Centers for Disease Control and Prevention, 2021). Communal confined
51 spaces such as public toilets in shopping centers, schools, restaurants, airports, theaters, and
52 hospitals may be significant areas for SARS-CoV-2 transmission (Dancer, Li, et al., 2021). Surface
53 contamination with SARS-CoV-2 in toilets and bathrooms has been reported (Ding, Qian, et al.,
54 2021; Maestre, Jarma, et al., 2021); however, transmission risks from fomite exposure could be
55 reduced significantly through the simple yet effective interventions of hand washing, hand
56 sanitizing, and surface disinfection (Dancer et al., 2021; World Health Organization [WHO],
57 2020a; Pitol & Julian, 2021). Airborne transmission, on the other hand, is deemed the main route

58 of COVID-19 spread (Centers for Disease Control and Prevention, 2021) and could be aggravated
59 by the use of busy, confined public toilet spaces, especially if appropriate steps are not taken to
60 mitigate the risk of virus transmission (Dancer, Li, et al., 2021).

61

62 The positive detection of SARS-CoV-2 RNA has been reported in 23.8% of air samples from
63 hospital toilets, which have demonstrated higher viral loads than clinical areas (Birgand, Peiffer-
64 Smadja, et al., 2020). However, risk assessments of respiratory exposure to SARS-CoV-2 in public
65 toilets is limited. Potential sources of infectious respiratory droplets and aerosol particles in toilet
66 settings include exhalation and expelling, such as sneezing, speaking, and coughing, by infected
67 toilet users, and the aerosolization of infected feces and urine after toilet flushing (Dancer, Li, et
68 al., 2021; Schijven, Vermeulen, et al., 2021). Although infectious SARS-CoV-2 was isolated from
69 the feces of a severely infected patient (Xiao, Sun, et al., 2020), studies confirming that feces and
70 urine in wastewater remain infectious for SARS-CoV-2 are limited, with supporting evidence
71 showing poor virus survival in gastrointestinal tracts due to the low pH of gastric fluids, bile,
72 digestive enzymes, and bacterial byproducts (Zang, Castro, et al., 2020; Albert, Ruíz, et al., 2021;
73 Jones, Baluja, et al., 2020). Consequently, even though flushing activities can produce airborne
74 droplets and aerosols, the associated risks may be low because contamination by infectious virus
75 particles is less likely (Shi, Huang, et al., 2021). In this study, we therefore focused on
76 characterizing the risk of SARS-CoV-2 respiratory transmission introduced by normal breathing
77 and expelling (i.e., coughing and sneezing) in a public toilet setting.

78

79 Quantitative microbial risk assessment (QMRA) is a valuable tool used to quantitatively estimate
80 human health risks associated with exposure to pathogens in different environmental matrices

81 (Rose and Gerba, 1991; Haas, Rose, et al., 2014). The QMRA framework has been applied to
82 estimate SARS-CoV-2 transmission risk to wastewater treatment plant workers (Dada and
83 Gyawali, 2021; Zaneti, Girardi, et al., 2021), Tokyo 2020 Olympic Games attendees (Murakami,
84 Miura, et al., 2021), and confined vehicle passengers and shared room users (Schijven, Vermeulen,
85 et al., 2021). In the present study, we aimed to estimate the risk of infection associated with public
86 toilet exposure to SARS-CoV-2 through airborne transmission using the QMRA approach. For
87 convenience, we called a healthy person who is exposed to transmission risk a receptor, while a
88 disease-carrying person, either symptomatic or asymptomatic, was termed an infector. We
89 gathered the input parameters from a variety of sources. These included COVID-19 concentration
90 data obtained by swab testing 251 Thai patients from a public hospital in Bangkok and the exposure
91 factors related to three droplet- and aerosol-generating activities of infectors, namely, breathing,
92 breathing with a cough, and breathing with a sneeze, which were all identified from published
93 sources (Schijven, Vermeulen, et al., 2021; Fabian, Brain, et al., 2011; Duguid, 1946; Han, Weng,
94 et al., 2013; Loudon and Roberts, 1967). The risk of infection was calculated separately for male
95 and female receptors because of their different respiratory rates and periods of time spent in the
96 toilet, the so-called dwell times. To include uncertainty and variability in the risk characterization,
97 we applied the Monte Carlo simulation technique to calculate the risks. The sensitivity of the model
98 parameters was evaluated to determine which input parameters could help reduce the associated
99 uncertainty. Finally, two risk mitigation measures, namely, face mask wearing and ventilation
100 improvement, were assessed to ascertain their efficacy. The calculated risks and associated
101 mitigation measures may be beneficial in the development of public health policies aimed at
102 providing effective control of SARS-CoV-2 transmission.

103

104 **MATERIALS AND METHODS**

105 **Risk scenarios**

106 We evaluated the infection risk in various scenarios with and without preventive measures. For
107 the public toilet model, a Thailand standard cubicle size of $1.5 \times 0.8 \times 2.7$ m (3.24 m^3) was set for
108 the risk evaluation (Ministry of Public Health, 2016). The three scenarios used in this study that
109 can cause an infector to generate infectious droplets and aerosols included breathing (Br),
110 breathing with a cough (Br+Co), and breathing with a sneeze (Br+Sn). The scenario that provided
111 the highest risk was further investigated to determine the efficacy of the identified mitigation
112 measures (i.e., face mask wearing and ventilation). To evaluate the effects of mask wearing,
113 different types of masks (i.e., N95 respirator and surgical and denim fabric masks) were modeled
114 when worn by either an infector or a receptor, or both. For the ventilation evaluation, the air
115 changes per hour (ACH) were varied at 0 (no ventilation), 0.5 (poor ventilation), 10 (DIN 1946
116 ventilation standard for public toilets), 12 (WHO recommended standard ventilation [2021]), and
117 20 (extreme ventilation). An outline of the QMRA steps for all the scenarios are presented in
118 Figure 1.

119

120 **Virus levels generated by an infector**

121 The SARS-CoV-2 concentrations used in this study were retrieved from the reverse-transcription
122 quantitative polymerase chain reaction quantification cycle (C_t) values of 251 positive swab test
123 results of an N2 gene from a public hospital in Bangkok from March to May 2021. Due to the
124 absence of a standard curve for clinical swab testing in Thailand, the viral concentrations were
125 estimated using a published standard curve (Sherchan, Shahin, et al., 2020), which ranged from
126 4.4×10^{-1} to 6.4×10^8 gene copies (gc)/ μL . The SARS-CoV-2 concentrations (A) were fitted with

127 a triangular distribution as shown in Table S1. To convert the virus concentrations from gc to an
128 infectious plaque-forming unit (PFU), the ratios of the PFU/gc (R) of SARS-CoV-2 between 1:100
129 and 1:1000 with a uniform distribution were applied (Pitol & Julian, 2021).

130

131 The number of infectious viruses suspended in the ambient air of the toilet cubicle was calculated
132 using the mass balance equation (Eq. 1) in which each term in the equation has units of mass per
133 time. Under the completely mixed condition, the accumulation of virus particles as aerosols was
134 obtained from the summation of the breathing of an infector, virus inactivation, and virus removal
135 by mechanical ventilation and inhalation. Under typical conditions of 20%–70% relative humidity,
136 a 20°C temperature, and no direct sunlight, an average SARS-CoV-2 inactivation rate of 0.008
137 (min^{-1}) was applied (Schuit, Ratnesar-Shumate, et al., 2020). We assumed that the virus particles
138 were released continually during the time the infector spent in the toilet cubicle (infector's dwell
139 time = t_I minutes). The dwell times for men and women, which were in line with those indicated
140 in an airport study (250 men and 237 women), were fitted with a log-normal distribution (Table
141 S1) (Gwynne, Hunt, et al., 2019). The remaining infectious virus concentrations generated by the
142 infector after leaving the toilet (C_{tI}) were calculated according to Eq. 2 by integrating Eq. 1 with
143 no initial virus particles ($C = 0$). The inhalation rates (q_{in}) following the uniform distribution ranged
144 between 8.36 and 19.74 L/min for men and 6.4 and 13.78 L/min for women (Brochu, Ducré-
145 Robitaille, et al., 2006). The additional concentrations of infectious SARS-CoV-2 expelled by
146 coughing (C_{co}) and sneezing (C_{sn}) were calculated using Eqs. 3 and 4, respectively. The volumetric
147 flow of droplets from an infector's exhalation (q_{br}) ranged from 5×10^{-9} to 6×10^{-6} $\mu\text{L}/\text{min}$
148 (Schijven, Vermeulen, et al., 2021). In addition, the volume of aerosol droplets expelled per cough
149 (V_{co}) and per sneeze (V_{sn}) was set according to the literature (Schijven, Vermeulen, et al., 2021).

150 However, the size of the droplets played an important role in their activity. The larger droplets
 151 deposited quickly, whereas the smaller droplets (aerosols) could remain suspended in the air for a
 152 longer period. Thus, the volumetric ratios of aerosols to total droplets expelled (F) were considered
 153 using a droplet size $\leq 70 \mu\text{m}$ based on the size distribution of droplets in the literature for breathing
 154 (Fabian, Brain, et al., 2011), coughing (Duguid, 1946; Han, Weng, et al., 2013; Loudon and
 155 Roberts, 1967) and sneezing (Duguid, 1946; Han, Weng, et al., 2013) (Table S1).

$$156 \quad \langle \text{Accumulation within system} \rangle = \langle \text{Flow in through system boundary} \rangle - \langle \text{Flow out through system boundary} \rangle - \langle \text{Reaction within system} \rangle \quad \text{Eq. 1.1}$$

$$157 \quad V \frac{dC}{dt} = q_{br} A R - \mu V C - q_{vent} C - q_{in} C \quad \text{Eq. 1.2}$$

$$158 \quad C_{t1} = \frac{q_{br} A R}{(\mu V + q_{vent} + q_{br})} \left(1 - e^{-\frac{\mu V + q_{vent} + q_{in}}{V} t_1} \right) \quad \text{Eq. 2}$$

$$159 \quad C_{co} = \frac{A V_{co} R F}{V} \quad \text{Eq. 3}$$

$$160 \quad C_{sn} = \frac{A V_{sn} R F}{V} \quad \text{Eq. 4}$$

161 where the parameters related to virus generation by an infector are:

162 q_{br} = volumetric flow of droplets from an infector's exhalation ($\mu\text{L-droplet}/\text{min}$)

163 A = virus concentrations in the genome copies per volume of droplets ($\text{gc}/\mu\text{L-droplet}$)

164 C_{co} = additional infectious virus concentrations in the air caused by a cough (PFU/L)

165 C_{sn} = additional infectious virus concentrations in the air caused by a sneeze (PFU/L)

166 R = PFU/gc ratio

167 F = fraction of aerosol volume per total volume of droplets expelled (dimensionless)

168 V_{co} = volume of aerosol expelled per cough ($\mu\text{L}/\text{cough}$)

169 V_{sn} = volume of aerosol expelled per sneeze ($\mu\text{L}/\text{sneeze}$)

170 q_{in} = inhalation rate (L/min)

171 q_{vent} = ventilation rate (L/min) that equals $ACH \times V/60$

172 V = volume of air in a cubicle (3,240 L-air)

173 t_I = infector's dwell time (min)

174 μ = inactivation rate in the air at 20%–70% relative humidity levels (min^{-1})

175


176 **Virus levels accessible to a receptor**

177 Because no input source of virus (no infector) was present, the term of flow in through a system
 178 boundary was discarded. To solve Eq. 5, the infectious virus concentrations the receptor (C_{t2}) was
 179 exposed to during the receptor's dwell time t_2 were calculated from Eq. 6. In this study, we
 180 assumed that after the infector exited the cubicle, the receptor immediately entered the cubicle.
 181 The initial concentrations (C_0) based on three scenarios (i.e., breathing only, breathing with a
 182 cough, and breathing with a sneeze [Eqs. 7–9]) were therefore incorporated into Eq. 6.

183

No source

184 $\langle \text{Accumulation within system} \rangle = \langle \text{Flow in through system boundary} \rangle - \langle \text{Flow out through system boundary} \rangle - \langle \text{Reaction within system} \rangle$ Eq. 5.1



185 $V \frac{dC}{dt} = -\mu V C - q_{vent} C - q_{in} C$ Eq. 5.2

186 $C_{t2} = C_0 \left(e^{-\frac{\mu V + q_{vent} + q_{in}}{V} t_2} \right)$ Eq. 6

187 Given C_0 based on the following specific scenarios:

188 Breathing only: $C_0 = C_{tI}$ Eq. 7

189 Breathing with a cough: $C_0 = C_{tI} + C_{co}$ Eq. 8

190 Breathing with a sneeze: $C_0 = C_{tI} + C_{sn}$ Eq. 9

191

192 **Virus doses inhaled by the receptor**

193 The virus doses (d) that would be inhaled by a receptor were calculated by incorporating the
194 inhalation rate (q_{in}) with a definite integral of the infectious virus concentration-time function (C_{t2}).
195 The limits of integration were set from $t = 0$ to the receptor's dwell time (t_2) (Eqs. 10.1–10.2). The
196 initial concentrations (C_0) also followed Eqs. 7–9 in line with the desired scenarios.

$$197 \quad d = q_{in} \int_{t=0}^{t=t_2} C_{t2} dt \quad \text{Eq. 10.1}$$

$$198 \quad d = \left(\frac{q_{in} V C_0}{\mu V + q_{vent} + q_{in}} \right) \left(1 - e^{-\frac{\mu V + q_{vent} + q_{in}}{V} t_2} \right) \quad \text{Eq. 10.2}$$

199

200 where t_2 = receptor's dwell time (min), and d = SARS-CoV-2 infectious dose (PFU).

201

202 **SARS-CoV-2 dose-response models**

203 The risk assessment was conducted by following the QMRA framework. Given the lack of dose-
204 response information for SARS-CoV-2, the SARS-CoV data sets (Watanabe, Bartrand, et al.,
205 2010) that had been utilized in various SARS-CoV-2 QMRA studies (Murakami, Miura, et al.,
206 2021; Dada and Gyawali, 2021; Zaneti, Girardi, et al., 2021; Cortellessa, Stabile, et al., 2021) were
207 applied. The risk of infection followed the exponential model (Eq. 11):

$$208 \quad P_{event} = 1 - e^{-\left(\frac{d}{k}\right)} \quad \text{Eq. 11}$$

209 where P_{event} is the probability of infection per event (probability), and k is the optimal dose
210 response function value of 4.1×10^2 , which is equivalent to the chance that a single pathogen
211 would initiate an infection response (Watanabe, Bartrand, et al., 2010).

212

213 **Risk characterization and sensitivity analysis**

214 To estimate the P_{event} for a receptor exposed to SARS-CoV-2, the data from the previous steps
215 were integrated into Monte Carlo simulations (MCs) with 10,000 iterations for each condition
216 using Oracle Crystal Ball software version 11.1.2.4.850. MCs is a randomization technique that
217 uses repeated random sampling from distributions given to key input variables in a model,
218 including corresponding uncertainty profiles. The risk of infection was displayed in the 2.5th
219 percentile, mean, and 97.5th percentile using a forest plot in GraphPad Prism version 7.0. It is
220 becoming increasingly important to fully consider the uncertainties, including those in the 97.5th
221 percentile, to maintain a sufficient safety margin for decision-making during the COVID-19
222 pandemic (Zhang, Ji, et al., 2021). The estimated risk was compared to a benchmark of 1 infection
223 per 20,000 exposed people per event (5×10^{-5}) (Murakami, Miura, et al., 2021). A sensitivity
224 analysis was also conducted to determine the effects of the input variables on the risk calculation.

225

226 **Risk management evaluation**

227 Two risk mitigation interventions were investigated: face mask wearing and ventilation. The
228 universal wearing of face masks has been recommended as a low-cost and efficient means of
229 mitigating virus transmission (WHO, 2020b). Among the different types of face masks,
230 predominantly N95 respirator and surgical and fabric masks are used worldwide. Viral filtration
231 efficiency (VFE) characterized using a bacteriophage MS2 following the ASTM F2101-14
232 standard testing method has revealed 99.8%–100% VFE for N95 respirators, 99.3%–99.8% VFE
233 for surgical masks, and 54.8%–92.1% for denim fabric masks (Whiley, Keerthirathne, et al., 2020)

234 (Table S1). MS2 bacteriophages were selected as the model microbes because they are two to three
235 times smaller in size than SARS-COV-2 (70–90 nm in diameter).

236

237 Ventilation is also an important element used to control indoor air quality in public toilets.
238 Depending on the applicable regulatory building standard, either the installation of a mechanical
239 ventilation system or the use of natural ventilation may be necessary. The effect of air change rates
240 on SARS-CoV-2 transmission risk was considered in this study. The DIN 1946 ventilation
241 standard is generally applied in public toilets. For the pandemic, the WHO has also suggested that
242 ventilation in indoor spaces with aerosol-generating potential should be greater than or equal to 12
243 ACH (WHO, 2021). In this study, five air change rates were tested: 0 ACH (no ventilation), 0.5
244 ACH (poor ventilation), 10 ACH (DIN 1946 ventilation standard for public toilets), 12 ACH
245 (WHO-recommended standard ventilation), and 20 ACH (extreme ventilation) (Table S1).

246

247 **RESULTS AND DISCUSSION**

248 **Infection risk from respiratory transmission in public toilets**

249 The risk of infection from SARS-CoV-2 transmission through three respiratory exposure
250 scenarios, namely, breathing, breathing with a cough, and breathing with a sneeze, were
251 characterized in this study. The probability of infection per event was not found to be significantly
252 different between men and women ($p > 0.05$; Mann–Whitney U test) across all scenarios (Figure
253 2 and Table S2). Although men usually have a higher breathing rate (Brochu et al., 2006), which
254 results in greater exposure to viruses, men spend on average around 22% less time in toilets than
255 women (Gwynne, Hunt, et al., 2019), leading to a reduced risk of virus transmission. When a
256 receptor without a protective mask was in an unventilated public toilet, the infection risk (97.5th

257 percentile) was 9.87×10^{-4} for men and 1.17×10^{-3} for women in the infector breathing scenario.
258 Interestingly, the risk values increased sharply when additional viral loads were expelled into the
259 air by an infector either sneezing or coughing (Figure 2 and Table S2). Coughing and sneezing can
260 produce saliva droplets of various sizes (Duguid, 1946; Han, Weng, et al., 2013; Loudon and
261 Roberts, 1967) and thus generate infectious virus-containing aerosols in public toilet facilities. For
262 breathing with a cough, the 97.5th percentile of risk was 2.17×10^{-1} for men and 2.15×10^{-1} for
263 women. Similarly, sneezing increased the risk of infection to 3.66×10^{-1} and 3.67×10^{-1} for men
264 and women, respectively. All the scenarios demonstrated higher risks than the 5×10^{-5} benchmark
265 value (Murakami, Miura, et al., 2021). We therefore showed that receptors had a high risk of
266 infection when using an unventilated public toilet without wearing a protective mask.

267

268 **Risk mitigation: face mask wearing**

269 *Face mask wearing in either an infector or a receptor*

270 Because it delivered the highest risk, the scenario with an infector breathing with a sneeze was
271 selected to further evaluate the effectiveness of face mask wearing to reduce infection risk in a
272 receptor. The probabilities of infection per event for different mask types are shown in Figure 3
273 and Table S3. All types of face masks considerably reduced the risk of infection. For example, an
274 N95 respirator could lead to an approximately 2-log reduction when worn by an infector and a 3-
275 log reduction when worn by a receptor. Interestingly, mask wearing by a receptor reduced the risk
276 of transmission to lower levels than when a mask was worn by an infector. However, the results
277 indicated that face mask wearing either by an infector or a receptor could still not decrease the risk
278 to below the suggested 5×10^{-5} benchmark. A high risk of virus transmission in confined spaces
279 like public toilets is therefore still possible even if an N95 respirator or surgical mask is worn. This

280 could be because the risk of infection is associated with several factors, including a high
281 concentration of virus aerosols in the ambient air due to insufficient ventilation, the long dwell
282 times of toilet users, the low inactivation rate of SAR-CoV-2, and the inadequate efficiency of
283 protective masks (Stabile, Pacitto, et al., 2021; Gwynne, Hunt, et al., 2019; Schuit, Ratnesar-
284 Shumate, et al., 2020; Whiley, Keerthirathne, et al., 2020). We also observed an at least 90% (1-
285 log) reduction in risk when an infector wore a denim fabric mask.

286

287 ***Face mask wearing in both an infector and a receptor***

288 In a scenario with an infector breathing with a sneeze, the infection risk could be further reduced
289 if both the infector and receptor wear masks (Table S3). The receptor's gender did not affect the
290 receptor's risk much in any of the conditions. The risks to a female receptor are illustrated in Figure
291 4. When a receptor wore an N95 respirator, the 97.5th percentile infection risk was reduced to
292 below the 5×10^{-5} benchmark no matter the type of mask, whether an N95 respirator or a surgical
293 or denim fabric mask, worn by the infector. When a receptor wore a surgical mask, the risk was
294 also reduced to below the benchmark with the exception of the case where the infector wore a
295 fabric mask. Denim fabric masks, on the other hand, may not provide sufficient protection even
296 when worn by both the infector and receptor. This study supports the recommendation for a person,
297 as a receptor, to use a surgical mask or an N95 respirator as personal protective equipment to
298 minimize the associated risk of infection in unventilated public toilets and potentially in other
299 confined communal spaces. In general, wearing a mask was shown to be one of the most low-cost,
300 simple yet effective intervention measures to minimize transmission risk, which is consistent with
301 reports from other studies (Asadi, Cappa, et al., 2020; Chu, Akl, et al., 2020; WHO, 2020b; Cheng,
302 Cheng, et al., 2021; Goyal, Reeves, et al., 2021).

303

304 **Risk mitigation: ventilation**

305 *Single measure: ventilation*

306 The effects of ventilation (0–20 ACH) were characterized for three virus-generating scenarios:
307 infector breathing, breathing with a cough, and breathing with a sneeze (Table S4). The breathing
308 with a sneeze scenario delivered the highest risk, and this worst-case condition was therefore
309 further assessed to determine the effects of ventilation using a representative female receptor
310 (Figure 5). The results showed that increasing ACH did not significantly mitigate the risk of
311 COVID-19 infection in the public toilet setting. Even at the 12 ACH suggested by the WHO (2021)
312 and the extreme condition of 20 ACH, the 97.5th percentile probabilities of infection per event for
313 the female receptor were still at the levels of 2.52×10^{-1} and 2.10×10^{-1} , respectively. Although a
314 high ventilation rate has been suggested as a way to reduce the number of virus-containing droplets
315 and aerosols in the air (WHO, 2021; Li, Qian, et al., 2021; Morawska, Tang, et al., 2020; Stabile,
316 Pacitto, et al., 2021), the continuous expelling of the SARS-CoV-2 virus from breathing and/or
317 sneezing by an infector without a mask appeared to be a significant cause of virus aerosol
318 accumulation in ambient air. This study demonstrated that indoor ventilation alone cannot
319 effectively reduce SARS-CoV-2 transmission risk in a public toilet setting and is less effective in
320 risk reduction than face mask wearing. Another study similarly found that masks could reduce the
321 infection risk caused by the Middle Eastern respiratory syndrome coronavirus in an indoor hospital
322 setting better than ventilation (Adhikari, Chabrelie, et al., 2019).

323

324 *Double measure: ventilation and face mask wearing*

325 The additional measure of mask wearing was further investigated for its combined effectiveness
326 in mitigating SARS-CoV-2 transmission risk when used simultaneously with increased
327 ventilation. In the virus-generating scenario with an infector breathing with a sneeze, mask wearing
328 by both the infector and receptor was assessed using ventilation of 10, 12, and 20 ACH (Figure 6).
329 When compared with no ACH (Figure 4), ventilation across all ACH values did not reduce the
330 infection risk to below the benchmark in any of the following four cases: denim fabric mask
331 wearing by the receptor and all three types of masks worn separately by the infector, and surgical
332 mask wearing by the receptor and denim fabric mask wearing by the infector. Consequently, we
333 reiterate that ventilation did not impact the risk mitigation for SARS-CoV-2 transmission in a
334 public toilet setting, especially in confined toilet cubicle conditions. Face mask wearing should
335 therefore be promoted as a normal practice when entering public indoor spaces.

336

337 **Sensitivity analysis of input parameters**

338 A sensitivity analysis of the QMRA was conducted to identify the input variables that most
339 contributed to the risk estimation. For all three transmission scenarios, namely, an infector
340 breathing (Br), breathing with a cough (Br+Co), and breathing with a sneeze (Br+Sn), the
341 concentration of SARS-CoV-2 virus in $gc/\mu L$ droplets (saliva and mucus) was the most sensitive
342 parameter, accounting for 34.3%–42.9% of the uncertainty in the probability of infection
343 transmission to either male or female receptors (Figure 7 and Table S5). The second and third most
344 sensitive parameters were the infector's expelled volume and the receptor's dwell time,
345 respectively. Since breathing with a sneeze was the highest virus-generating risk scenario, a
346 sensitivity analysis was performed in which both the infector and receptor wore masks (Table S6).
347 Virus concentrations in $gc/\mu L$, sneeze volume, and the receptor's dwell time were the three

348 parameters that most influenced infection risk. Since controlling for virus concentrations and an
349 infector's expelled volume are a challenge, particularly among asymptomatic patients, individuals
350 should avoid spending prolonged time in closed indoor settings (Dancer, Li, et al., 2021; Stabile,
351 Pacitto, et al., 2021).

352

353 **Limitations of this study and future perspectives**

354 While this study evaluated the risk of SARS-CoV-2 transmission according to the QMRA
355 framework, its limitations and uncertainties should be carefully acknowledged. SARS-CoV-2
356 concentrations in gc/ μ L, the most sensitive parameter affecting the calculation of risk, are subject
357 to natural variations in the saliva and mucus of infected patients (Azzi, Carcano, et al., 2020;
358 Wölfel, Corman, et al., 2020). In this study, 251 swab test C_t values were used to represent the
359 virus levels in Thai patients. Due to the lack of a standard curve from Thai hospital laboratories,
360 we used a published standard curve of the N2 gene (Sherchan, Shahin, et al., 2020) to estimate the
361 virus concentrations in this study. However, heterogeneity in published standard curves for SARS-
362 CoV-2 has been observed (Bivins, Kaya, et al., 2021). Moreover, variations in technical and
363 laboratory analyses (e.g., data analysis methods and control materials) could intensify biases,
364 leading to variability in the calculated virus concentrations (Bivins, Kaya, et al., 2021; Kongprajug,
365 Chyerochana, et al., 2020). Adhering to standards and quality control measures is therefore
366 underlined in order to support data sharing and referencing for future research, especially for
367 emerging infectious diseases. However, even with consideration of the uncertainties mentioned
368 above, the calculated virus concentrations in mucus used in this study, which ranged from $4.4 \times$
369 10^{-1} to 6.4×10^8 gc/ μ L, were in agreement with those from another report (Schijven, Vermeulen,
370 et al., 2021).

371
372 We chose to evaluate three virus-generating scenarios: an inceptor breathing, breathing with a
373 cough, and breathing with a sneeze. However, infectors may sneeze and/or cough more than once
374 depending on the individuals' symptoms. Coughing is the predominant symptom in COVID-19
375 (Wang, Yang, et al., 2020), rendering coughing potentially more important than sneezing.
376 Nevertheless, some studies have suggested that airborne transmission of infectious diseases is
377 possible without coughing or sneezing and simply from exhaled breath from individuals who show
378 barely any symptoms (Asadi, Bouvier, et al., 2020). In addition, the lack of dose-response
379 information and risk of infection benchmarks for SARS-CoV-2 poses a challenge when evaluating
380 its infection risk. We assumed that the dose-response of SARS-CoV-2 was similar to that indicated
381 in the SARS-CoV data (Watanabe, Bartrand, et al., 2010), which has been utilized in various
382 QMRA studies of SARS-CoV-2 (Murakami, Miura, et al., 2021; Dada and Gyawali, 2021; Zaneti,
383 Girardi, et al., 2021; Cortellessa, Stabile, et al., 2021). With the recent emergence of various
384 SARS-CoV-2 variants, much remains unknown regarding the behavior and characteristics of this
385 virus. This study used the available inactivation coefficients of SARS-CoV-2 at 20°C (Schuit,
386 Ratnesar-Shumate, et al., 2020), which could have overestimated the calculated risks in Thailand
387 given its average daily temperature of 27.48°C (Denpetkul & Phosri, 2021).

388
389 Furthermore, the scope of this study excluded the risk of SARS-CoV-2 respiratory transmission
390 potentially produced by toilet flushing, as well as other transmission risks (e.g., direct splashing
391 and surface transmission). By integrating all the known risk sources, comprehensive knowledge
392 regarding risk estimation could be achieved to accurately inform public health policy and further
393 help reduce transmission risk. It is apparent that research related to SARS-CoV-2 is continuing,

394 and additional data will greatly benefit future studies aiming to better understand its characteristics.
395 The QMRA-based risk models developed in this study could facilitate future risk assessments
396 through modifications for particular risk scenarios and the updating of the input parameters based
397 on newly available data. Such improved risk models will be crucial tools in assessing the impact
398 of different risk mitigation strategies during the COVID-19 and future pandemics.

399

400 **CONCLUSIONS**

401 Indoor public toilet facilities could be hubs of virus transmission during the COVID-19 pandemic.
402 This study investigated the risk of airborne transmission of SARS-CoV-2 in public toilets for three
403 virus-generating scenarios: an infector breathing, breathing with a cough, and breathing with a
404 sneeze. The risk analysis, which followed the QMRA framework, revealed that the highest risk
405 was when an asymptomatic or symptomatic infector sneezed. Both genders were found to be
406 exposed to similar risks. Toilet ventilation systems cannot effectively mitigate transmission risk,
407 so an effective intervention would be for public toilet users to wear either surgical masks or N95
408 respirators.

409

410 **Conflict of interest**

411 The authors declare that they have no conflict of interest in this work.

412

413 **Acknowledgments**

414 This work was financially supported by the Chulabhorn Research Institute (grant no. 312/3057)
415 and the Mahidol University. The authors would like to acknowledge Associate Professor

416 Pornsawan Leungwutiwong from the Department of Microbiology and Immunology, Faculty of
417 Tropical Medicine, Mahidol University for providing the COVID-19 Ct values from swab testing.

418

419 **Supplementary Material**

420 Supplementary material for this manuscript is available.

421

422 **References**

423 Adhikari, U., Chabrelie, A., Weir, M., Boehnke, K., McKenzie, E., Ikner, L., Wang, M., Wang, Q., Young,
424 K., Haas, C. N., Rose, J., and Mitchell, J. (2019) A Case Study Evaluating the Risk of Infection from
425 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) in a Hospital Setting Through
426 Bioaerosols. *Risk Analysis*, **39**(12), 2608–2624.

427 Albert, S., Ruíz, A., Pemán, J., Salavert, M., and Domingo-Calap, P. (2021) Lack of evidence for infectious
428 SARS - CoV - 2 in feces and sewage. *European Journal of Clinical Microbiology & Infectious
429 Diseases*, (0123456789), 2–4. [online] <https://doi.org/10.1007/s10096-021-04304-4>.

430 Asadi, S., Bouvier, N., Wexler, A. S., and Ristenpart, W. D. (2020) The coronavirus pandemic and aerosols:
431 Does COVID-19 transmit via expiratory particles? *Aerosol Science and Technology*, **54**(6), 635–638.

432 Asadi, S., Cappa, C. D., Barreda, S., Wexler, A. S., Bouvier, N. M., and Ristenpart, W. D. (2020) Efficacy
433 of masks and face coverings in controlling outward aerosol particle emission from expiratory
434 activities. *Scientific reports*, **10**(1), 15665. [online] <http://www.ncbi.nlm.nih.gov/pubmed/32973285>.

435 Azzi, L., Carcano, G., Gianfagna, F., Grossi, P., Gasperina, D. D., Genoni, A., Fasano, M., Sessa, F.,
436 Tettamanti, L., Carinci, F., Maurino, V., Rossi, A., Tagliabue, A., and Baj, A. (2020) Saliva is a
437 reliable tool to detect SARS-CoV-2. *Journal of Infection*, **81**(1), e45–e50. [online]
438 <https://doi.org/10.1016/j.jinf.2020.04.005>.

439 Birgand, G., Peiffer-Smadja, N., Fournier, S., Kerneis, S., Lescure, F. X., and Lucet, J. C. (2020)
440 Assessment of Air Contamination by SARS-CoV-2 in Hospital Settings. *JAMA Network Open*, **3**(12),

- 441 1–14.
- 442 Bivins, A., Kaya, D., Bibby, K., Simpson, S. L., Bustin, S. A., Shanks, O. C., and Ahmed, W. (2021)
- 443 Variability in RT-qPCR assay parameters indicates unreliable SARS- CoV-2 RNA quantification for
- 444 wastewater surveillance. *Water Research*, 117516. [online]
- 445 <https://doi.org/10.1016/j.watres.2021.117516>.
- 446 Brochu, P., Ducré-Robitaille, J. F., and Brodeur, J. (2006) Physiological daily inhalation rates for free-
- 447 living pregnant and lactating adolescents and women aged 11 to 55 years, using data from doubly
- 448 labeled water measurements for use in health risk assessment. *Human and Ecological Risk*
- 449 *Assessment*, **12**(4), 702–735.
- 450 CDC (2021) COVID-19 Scientific Brief: SARS-CoV-2 Transmission. Updated May 7, 2021.
- 451 Cheng, Y, Cheng, Yafang, Ma, N., Witt, C., Rapp, S., Wild, P. S., and Andreae, M. O. (2021) Face masks
- 452 effectively limit the probability of SARS-CoV-2 transmission. *Science*, **6296**(May), 1–11.
- 453 Chu, D. K., Akl, E. A., Duda, S., Solo, K., Yaacoub, S., Schünemann, H. J., El-harakeh, A., Bognanni, A.,
- 454 Lotfi, T., Loeb, M., Hajizadeh, A., Bak, A., Izcovich, A., Cuello-Garcia, C. A., Chen, C., Harris, D.
- 455 J., Borowiack, E., Chamseddine, F., Schünemann, F., Morgano, G. P., Muti Schünemann, G. E. U.,
- 456 Chen, G., Zhao, H., Neumann, I., Chan, J., Khabsa, J., Hneiny, L., Harrison, L., Smith, M., Rizk, N.,
- 457 Giorgi Rossi, P., AbiHanna, P., El-khoury, R., Stalteri, R., Baldeh, T., Piggott, T., Zhang, Y., Saad,
- 458 Z., Khamis, A., and Reinap, M. (2020) Physical distancing, face masks, and eye protection to prevent
- 459 person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-
- 460 analysis. *The Lancet*, **395**(10242), 1973–1987.
- 461 Cortellessa, G., Stabile, L., Arpino, F., Faleiros, D. E., van den Bos, W., Morawska, L., and Buonanno, G.
- 462 (2021) Close proximity risk assessment for SARS-CoV-2 infection. *Science of the Total Environment*,
- 463 **794**, 148749. [online] <https://doi.org/10.1016/j.scitotenv.2021.148749>.
- 464 Dada, A. C. and Gyawali, P. (2021) Quantitative microbial risk assessment (QMRA) of occupational
- 465 exposure to SARS-CoV-2 in wastewater treatment plants. *Science of the Total Environment*, **763**,
- 466 142989. [online] <https://doi.org/10.1016/j.scitotenv.2020.142989>.

- 467 Dancer, S. J., Li, Y., Hart, A., Tang, J. W., and Jones, D. L. (2021) What is the risk of acquiring SARS-
468 CoV-2 from the use of public toilets? *Science of the Total Environment*, 148341. [online]
469 <https://doi.org/10.1016/j.phrs.2020.104743>.
- 470 Denpetkul, T. and Phosri, A. (2021) Daily ambient temperature and mortality in Thailand : Estimated
471 effects , attributable risks , and effect modifications by greenness. *Science of the Total Environment*,
472 **791**, 148373. [online] <https://doi.org/10.1016/j.scitotenv.2021.148373>.
- 473 Ding, Z., Qian, H., Xu, B., Huang, Y., Miao, T., Yen, H., Xiao, S., Cui, L., Wu, X., Shao, W., Song, Y.,
474 Sha, L., Zhou, L., Xu, Y., Zhu, B., and Li, Y. (2021) Toilets dominate environmental detection of
475 severe acute respiratory syndrome coronavirus 2 in a hospital. *Science of the Total Environment*, **753**,
476 141710. [online] <https://doi.org/10.1016/j.scitotenv.2020.141710>.
- 477 Duguid, J. P. (1946) The size and the duration of air-carriage of respiratory droplets and droplet-nuclei.
478 *Journal of Hygiene*, **44**(6), 471–479.
- 479 Fabian, P., Brain, J., Houseman, E. A., Gern, J., and Milton, D. K. (2011) Origin of exhaled breath particles
480 from healthy and human rhinovirus-infected subjects. *Journal of Aerosol Medicine and Pulmonary*
481 *Drug Delivery*, **24**(3), 137–147.
- 482 Goyal, A., Reeves, D. B., Thakkar, N., Famulare, M., Cardozo-Ojeda, E. F., Mayer, B. T., and Schiffer, J.
483 T. (2021) Slight reduction in SARS-CoV-2 exposure viral load due to masking results in a significant
484 reduction in transmission with widespread implementation. *Scientific Reports*, **11**(1), 1–12. [online]
485 <https://doi.org/10.1038/s41598-021-91338-5>.
- 486 Gwynne, S. M. V., Hunt, A. L. E., Thomas, J. R., Thompson, A. J. L., and Séguin, L. (2019) The toilet
487 paper: Bathroom dwell time observations at an airport. *Journal of Building Engineering*, **24**(March),
488 100751. [online] <https://doi.org/10.1016/j.jobe.2019.100751>.
- 489 Haas, C. N., Rose, J. B., and Gerba, C. P. (2014) *Quantitative microbial risk assessment*, Wiley.
- 490 Han, Z. Y., Weng, W. G., and Huang, Q. Y. (2013) Characterizations of particle size distribution of the
491 droplets exhaled by sneeze. *Journal of the Royal Society Interface*, **10**(88).
- 492 Jones, D. L., Baluja, M. Q., Graham, D. W., Corbishley, A., McDonald, J. E., Malham, S. K., Hillary, L.

- 493 S., Connor, T. R., Gaze, W. H., Moura, I. B., Wilcox, M. H., and Farkas, K. (2020) Shedding of
494 SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the
495 environment-based spread of COVID-19. *Science of the Total Environment*, **749**(July), 141364.
496 [online] <https://doi.org/10.1016/j.scitotenv.2020.141364>.
- 497 Kongprajug, A., Chyerochana, N., Mongkolsuk, S., and Sirikanchana, K. (2020) Effect of quantitative
498 polymerase chain reaction data analysis using sample amplification efficiency on microbial source
499 tracking assay performance and source attribution. *Environmental Science & Technology*, **54**, 8232–
500 8244.
- 501 Li, Y., Qian, H., Hang, J., Chen, X., Cheng, P., Ling, H., Wang, S., Liang, P., Li, J., Xiao, S., Wei, J., Liu,
502 L., Cowling, B. J., and Kang, M. (2021) Probable airborne transmission of SARS-CoV-2 in a poorly
503 ventilated restaurant. *Building and Environment*, **196**(March), 107788. [online]
504 <https://doi.org/10.1016/j.buildenv.2021.107788>.
- 505 Loudon, R. G. and Roberts, R. M. (1967) Droplet expulsion from the respiratory tract. *American Review*
506 *of Respiratory Disease*, **95**(3), 435–442.
- 507 Maestre, J. P., Jarma, D., Yu, C., Siegel, J., Horner, S., and Kinney, K. A. (2021) Distribution of SARS-
508 CoV-2 RNA signal in a home with COVID-19 positive occupants. *Science of the Total Environment*,
509 **778**, 146201. [online] <https://doi.org/10.1016/j.scitotenv.2021.146201>.
- 510 Ministry of Public Health (2016) *Standard construction plan and layout for public toilets*. Bureau of
511 *Environmental Health*. Department of Health. Ministry of Public Health. Thailand.,
- 512 Morawska, L., Tang, J. W., Bahnfleth, W., Bluyssen, P. M., Boerstra, A., Buonanno, G., Cao, J., Dancer,
513 S., Floto, A., Franchimon, F., Haworth, C., Hogeling, J., Isaxon, C., Jimenez, J. L., Kurnitski, J., Li,
514 Y., Loomans, M., Marks, G., Marr, L. C., Mazzeo, L., Melikov, A. K., Miller, S., Milton, D. K.,
515 Nazaroff, W., Nielsen, P. V., Noakes, C., Peccia, J., Querol, X., Sekhar, C., Seppänen, O., Tanabe, S.
516 ichi, Tellier, R., Tham, K. W., Wargoeki, P., Wierzbicka, A., and Yao, M. (2020) How can airborne
517 transmission of COVID-19 indoors be minimised? *Environment International*, **142**(April).
- 518 Murakami, M., Miura, F., Kitajima, M., Fujii, K., Yasutaka, T., Iwasaki, Y., Ono, K., Shimazu, Y., Sorano,

- 519 S., Okuda, T., Ozaki, A., Katayama, K., Nishikawa, Y., Kobashi, Y., Sawano, T., Abe, T., Saito, M.
520 M., Tsubokura, M., Naito, W., and Imoto, S. (2021) COVID-19 risk assessment at the opening
521 ceremony of the Tokyo 2020 Olympic Games. *Microbial Risk Analysis*, (November 2020), 100162.
522 [online] <https://doi.org/10.1016/j.mran.2021.100162>.
- 523 Pitol, A. K. and Julian, T. R. (2021) Community Transmission of SARS-CoV-2 by Surfaces: Risks and
524 Risk Reduction Strategies. *Environmental Science and Technology Letters*, **8**(3), 263–269.
- 525 Rose, J. B. and Gerba, C. P. (1991) Use of risk assessment for development of microbial standards. *Water*
526 *Science and Technology*, **24**(2), 29–34.
- 527 Schijven, J., Vermeulen, L. C., Swart, A., Meijer, A., Duizer, E., and de Roda Husman, A. M. (2021)
528 Quantitative microbial risk assessment for airborne transmission of sars-cov-2 via breathing,
529 speaking, singing, coughing, and sneezing. *Environmental Health Perspectives*, **129**(4), 1–10.
- 530 Schuit, M., Ratnesar-Shumate, S., Yolitz, J., Williams, G., Weaver, W., Green, B., Miller, D., Krause, M.,
531 Beck, K., Wood, S., Holland, B., Bohannon, J., Freeburger, D., Hooper, I., Biryukov, J., Altamura, L.
532 A., Wahl, V., Hevey, M., and Dabisch, P. (2020) Airborne SARS-CoV-2 is rapidly inactivated by
533 simulated sunlight. *Journal of Infectious Diseases*, **222**(4), 564–571.
- 534 Sherchan, S. P., Shahin, S., Ward, L. M., Tandukar, S., Aw, T. G., Schmitz, B., Ahmed, W., and Kitajima,
535 M. (2020) First detection of SARS-CoV-2 RNA in wastewater in North America: A study in
536 Louisiana, USA. *Science of the Total Environment*, **743**, 140621. [online]
537 <https://doi.org/10.1016/j.scitotenv.2020.140621>.
- 538 Shi, K. W., Huang, Y. H., Quon, H., Ou-Yang, Z. L., Wang, C., and Jiang, S. C. (2021) Quantifying the
539 risk of indoor drainage system in multi-unit apartment building as a transmission route of SARS-CoV-
540 2. *Science of the Total Environment*, **762**, 143056. [online]
541 <https://doi.org/10.1016/j.scitotenv.2020.143056>.
- 542 Stabile, L., Pacitto, A., Mikszewski, A., Morawska, L., and Buonanno, G. (2021) Ventilation procedures to
543 minimize the airborne transmission of viruses in classrooms. *Building and Environment*, **202**(March),
544 108042. [online] <https://doi.org/10.1016/j.buildenv.2021.108042>.

- 545 Wang, Z., Yang, B., Li, Q., Wen, L., and Zhang, R. (2020) Clinical features of 69 cases with coronavirus
546 disease 2019 in Wuhan, China. *Clinical Infectious Diseases*, **71**(15), 769–777.
- 547 Watanabe, T., Bartrand, T. A., Weir, M. H., Omura, T., and Haas, C. N. (2010) Development of a dose-
548 response model for SARS coronavirus. *Risk Analysis: An International Journal*, **30**(7), 1129–1138.
- 549 Whiley, H., Keerthirathne, T. P., Nisar, M. A., White, M. A. F., and Ross, K. E. (2020) Viral filtration
550 efficiency of fabric masks compared with surgical and n95 masks. *Pathogens*, **9**(9), 1–8.
- 551 WHO (2020a) Considerations for public health and social measures in the workplace in the context of
552 COVID-19. World Health Organisation, (May), 1. [online] [https://www.who.int/publications-](https://www.who.int/publications-detail/risk-)
553 [detail/risk-](https://www.who.int/publications-detail/risk-) (Accessed August 7, 2021).
- 554 WHO (2020b) Coronavirus disease (COVID-19) advice for the public: When and how to use masks. ,
555 (December 2020). [online] [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks)
556 [2019/advice-for-public/when-and-how-to-use-masks](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks) (Accessed August 8, 2021).
- 557 WHO (2021) *Roadmap to improve and ensure good indoor ventilation in the context of COVID-19* (World
558 Health Organization, ed.), World Health Organization.
- 559 Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones,
560 T. C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J., Ehmann, R.,
561 Zwirgmaier, K., Drosten, C., and Wendtner, C. (2020) Virological assessment of hospitalized patients
562 with COVID-2019. *Nature*, **581**(7809), 465–469.
- 563 Xiao, F., Sun, J., Xu, Y., Li, F., Huang, X., Li, H., Zhao, Jingxian, Huang, J., and Zhao, Jincun (2020)
564 Infectious SARS-CoV-2 in feces of patient with severe COVID-19. *Emerging Infectious Diseases*,
565 **26**(8), 1920–1922.
- 566 Zaneti, R. N., Girardi, V., Spilki, F. R., Mena, K., Westphalen, A. P. C., da Costa Colares, E. R., Pozzebon,
567 A. G., and Etchepare, R. G. (2021) Quantitative microbial risk assessment of SARS-CoV-2 for
568 workers in wastewater treatment plants. *Science of the Total Environment*, **754**, 142163. [online]
569 <https://doi.org/10.1016/j.scitotenv.2020.142163>.
- 570 Zang, R., Castro, M. F. G., McCune, B. T., Zeng, Q., Rothlauf, P. W., Sonnek, N. M., Liu, Z., Brulois, K.

571 F., Wang, X., Greenberg, H. B., Diamond, M. S., Ciorba, M. A., Whelan, S. P. J., and Ding, S. (2020)
572 TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes.
573 Science Immunology, **5**(47), 1–14.

574 Zhang, X., Ji, Z., Yue, Y., Liu, H., and Wang, J. (2021) Infection Risk Assessment of COVID-19 through
575 Aerosol Transmission: A Case Study of South China Seafood Market. Environmental Science and
576 Technology, **55**(7), 4123–4133.

577

578 **Figure legends**

579 **Figure 1.** Outline of the QMRA steps for the scenarios associated with SARS-CoV-2 respiratory
580 transmission in a public toilet setting

581 **Figure 2.** Risk of infection per event for a male (M) or female (F) receptor in three virus-generating
582 scenarios: an infector breathing (Br), breathing with a cough (Br+Co), and breathing with a sneeze
583 (Br+Sn). The forest plots show the mean values in solid circles and 95% confidence intervals
584 (ranging from the 2.5th [left whiskers] to the 97.5th [right whiskers] percentiles). The dashed line
585 indicates the 5×10^{-5} benchmark value.

586 **Figure 3.** Risk of infection per event among male (M) and female (F) receptors in the scenario
587 with an infector (I) breathing with a sneeze (Br+Sn) when (a) only the infector wore different types
588 of masks and (b) only the receptor (R) wore different types of masks. The forest plots show the
589 mean values in solid circles and 95% confidence intervals (ranging from the 2.5th [left whiskers]
590 to the 97.5th [right whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.

591 **Figure 4.** The risk of infection per event in a scenario with an infector (I) breathing with a sneeze
592 (Br+Sn) when both the infector and receptor (R) wore different types of masks. The risks to a
593 female receptor are represented because no gender effect was evident. The forest plots show the

594 mean values in solid circles and 95% confidence intervals (ranging from the 2.5th [left whiskers]
595 to the 97.5th [right whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.

596 **Figure 5.** The risk of infection per event in a scenario with an infector breathing with a sneeze
597 (Br+Sn) with 0, 0.5, 10, 12, and 20 air changes per hour (ACH). The risks to a female receptor are
598 represented because no gender effect was evident. The forest plots show the mean values in solid
599 circles and 95% confidence intervals (ranging from the 2.5th [left whiskers] to the 97.5th [right
600 whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.


601 **Figure 6.** The risk of infection per event in a scenario with an infector (I) breathing with a sneeze
602 (Br+Sn) when the infector wore different types of masks, the receptor (R) wore different types of
603 masks, and the air change per hour was (a) 10 ACH, (b) 12 ACH, and (c) 20 ACH. The risks to a
604 female receptor are represented because no gender effect was evident. The forest plots show the
605 mean values in solid circles and 95% confidence intervals (ranging from the 2.5th [left whiskers]
606 to the 97.5th [right whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.

607 **Figure 7.** The sensitivity analysis representing the contribution of input variables to the risk of
608 infection per event for male and female receptors in three transmission scenarios, namely, with the
609 infector breathing (Br), breathing with a cough (Br+Co), and breathing with a sneeze (Br+Sn): (a)
610 infector's Br to a female receptor, (b) infector's Br to a male receptor, (c) infector's Br+Co to a
611 female receptor, (d) infector's Br+Co to a male receptor, (e) infector's Br+Sn to a female receptor,
612 and (f) infector's Br+Sn to a male receptor.

613

614


615



616

617 **Figure 1.** Outline of the QMRA steps for the scenarios associated with SARS-CoV-2 respiratory
 618 transmission in a public toilet setting


619



620

621 **Figure 2.** Risk of infection per event for a male (M) or female (F) receptor in three virus-generating
 622 scenarios: an infector breathing (Br), breathing with a cough (Br+Co), and breathing with a sneeze
 623 (Br+Sn). The forest plots show the mean values in solid circles and 95% confidence intervals
 624 (ranging from the 2.5th [left whiskers] to the 97.5th [right whiskers] percentiles). The dashed line
 625 indicates the 5×10^{-5} benchmark value.


626




627

628 **Figure 3.** Risk of infection per event among male (M) and female (F) receptors in the scenario
 629 with an infector (I) breathing with a sneeze (Br+Sn) when (a) only the infector wore different types
 630 of masks and (b) only the receptor (R) wore different types of masks. The forest plots show the
 631 mean values in solid circles and 95% confidence intervals (ranging from the 2.5th [left whiskers]
 632 to the 97.5th [right whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.


633



634
 635 **Figure 4.** The risk of infection per event in a scenario with an infector (I) breathing with a sneeze
 636 (Br+Sn) when both the infector and receptor (R) wore different types of masks. The risks to a
 637 female receptor are represented because no gender effect was evident. The forest plots show the
 638 mean values in solid circles and 95% confidence intervals (ranging from the 2.5th [left whiskers]
 639 to the 97.5th [right whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.
 640
 641




642
 643 **Figure 5.** The risk of infection per event in a scenario with an infector breathing with a sneeze
 644 (Br+Sn) with 0, 0.5, 10, 12, and 20 air changes per hour (ACH). The risks to a female receptor are
 645 represented because no gender effect was evident. The forest plots show the mean values in solid
 646 circles and 95% confidence intervals (ranging from the 2.5th [left whiskers] to the 97.5th [right
 647 whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.
 648



649

650 **Figure 6.** The risk of infection per event in a scenario with an infector (I) breathing with a sneeze
651 (Br+Sn) when the infector wore different types of masks, the receptor (R) wore different types of
652 masks, and the air change per hour was (a) 10 ACH, (b) 12 ACH, and (c) 20 ACH. The risks to a
653 female receptor are represented because no gender effect was evident. The forest plots show the
654 mean values in solid circles and 95% confidence intervals (ranging from the 2.5th [left whiskers]
655 to the 97.5th [right whiskers] percentiles). The dashed line indicates the 5×10^{-5} benchmark value.

656



657

658 **Figure 7.** The sensitivity analysis representing the contribution of input variables to the risk of
 659 infection per event for male and female receptors in three transmission scenarios, namely, with the
 660 infector breathing (Br), breathing with a cough (Br+Co), and breathing with a sneeze (Br+Sn): (a)
 661 infector's Br to a female receptor, (b) infector's Br to a male receptor, (c) infector's Br+Co to a
 662 female receptor, (d) infector's Br+Co to a male receptor, (e) infector's Br+Sn to a female receptor,
 663 and (f) infector's Br+Sn to a male receptor.